# AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

> **NCT00454805** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 75 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** AZD2171
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT00454805
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-12
- **Final completion:** 2016-04
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2016-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454805, "AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00454805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*